…That booster (mRNA-1273.222), which the FDA is calling an updated booster, combines the original vaccine with Omicron subvariant BA.4/BA.5 spike proteins. Due to an absence of data, authorization was based on the safety results of the mRNA-1273.214 study cited above and an unpublished preclinical study, which reported little additional benefit with the updated booster compared to the mRNA-1273.214 booster even against the BA.5 subvariant (Scheaffe…

…canada/toronto/ontario-covid-19-ba5-wave-1.6512283). As of June 19, 81.9% of Canadians had completed a primary series of COVID vaccinations and 48.9% had received one booster injection. For the fall, the National Advisory Committee on Immunization (NACI) recommends a booster shot for all at-risk groups; a booster may also be offered to individuals aged 12-64 years. Quebec is now recommending a fourth dose for all persons aged >60 years….

…0.8 vs. 630.5) and 180 days post-injection (GMT 312.9 vs. 145.6). The most common systemic adverse reactions with the bivalent booster were fatigue (64%), headache (51%) and myalgia (49%). The second Moderna booster, mRNA-1273.214, combines the standard vaccine with Omicron-specific antigens and is the lead candidate for use as the new booster injection this fall. The data have not been published but have been presented at an investor meeting. All…